Dizal receives approval in China for NSCLC therapy

Dizal has received approval from China’s NMPA for sunvozertinib to treat adult patients with locally advanced or metastatic NSCLC

Aug 24, 2023 - 20:00

Dizal receives approval in China for NSCLC therapy

Dizal has received approval from China’s NMPA for sunvozertinib to treat adult patients with locally advanced or metastatic NSCLC

Read the original article

Tags:

Previous Article

Japan grants patent for BioArctic’s Parkinson’s disease antibody

Spanish pharmaceutical company Serra Pamies faces EMA production restrictions

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Star Therapeutics raises $90m in funding to advance antibody therapies

Star Therapeutics raises $90m in funding to advance ant...

Sep 5, 2023

Listen: Messy PBM conflicts, debatable vaccines, & the ...

Jun 22, 2023

Novartis snaps up rare disease biotech DTx Pharma in $1bn deal

Novartis snaps up rare disease biotech DTx Pharma in $1...

Jul 19, 2023